At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
OncLive® On Air
32 minutes
1 week ago
S14 Ep33: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.
OncLive® On Air
At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.
